Search XGN
EXAGEN INC.
Nasdaq · CIK 1274737
Last close8.17
Daily change+0.28 (3.55%)
10 Years gain-52.25%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
XGN · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
62.1Momentum
92.7Acceleration
78.6Confidence
83.0Annual Revenue8
Quarterly Revenue24
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.5 / 25
Quality20.3 / 25
Capital Efficiency4.0 / 20
Balance Sheet13.3 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 1.1014 percentage points.
Operating leverageOperating margin improved by 8.5338 percentage points.
ROIC expansionROIC improved by 1.5181 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 30.2153%.
Key Metrics
Revenue Growth TTM24.72%OK
Revenue CAGR 3Y13.47%OK
Gross Margin59.83%OK
Operating Margin-15.16%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-45.41%OK
Incremental Operating Margin 3Y87.63%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y30.22%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $66.58M | $38.80M | -$14.07M | -$13.63M | -$14.27M | 58.28% | -21.13% | -21.43% | -139.95% | 21.56M |
| 2025 FY Dec 31, 2024 | $55.64M | $33.11M | -$13.64M | -$13.28M | -$13.79M | 59.51% | -24.51% | -24.79% | -160.24% | 18.2M |
| 2024 FY Dec 31, 2023 | $52.55M | $29.46M | -$22.84M | -$14.46M | -$15.29M | 56.06% | -43.46% | -29.1% | -244.91% | 17.68M |
| 2023 FY Dec 31, 2022 | $45.56M | $21.35M | -$46.05M | -$32.14M | -$36.46M | 46.86% | -101.07% | -80.03% | -330.59% | 17.08M |
| 2022 FY Dec 31, 2021 | $48.30M | $27.71M | -$24.07M | -$20.27M | -$22.64M | 57.37% | -49.83% | -46.87% | -158.3% | 15.97M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $71.69M | sum latest 4 fiscal quarters Revenue | OK | 0001274737-26-000048, 0001274737-25-000071 |
| Revenue Growth TTM | 24.72% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001274737-26-000048, 0001274737-25-000071 |
| Revenue CAGR 3Y | 13.47% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001274737-26-000009 |
| Revenue CAGR 5Y | 9.66% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001274737-26-000009 |
| Gross Profit CAGR 3Y | 22.03% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001274737-26-000009 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001274737-26-000048, 0001274737-25-000071 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 59.83% | Gross Profit / Revenue | OK | 0001274737-26-000048, 0001274737-25-000071 |
| Operating Margin | -15.16% | Operating Income / Revenue | OK | 0001274737-26-000048, 0001274737-25-000071 |
| ROIC | -45.41% | NOPAT / Average Invested Capital | OK | 0001274737-26-000048, 0001274737-25-000071 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001274737-26-000048 |
| Current Ratio | 3.18x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.08x | (Cash + Short-term Investments) / Total Debt | OK | 0001274737-26-000048 |
| Revenue per Diluted Share | $2.97 | Revenue / Diluted Shares | OK | 0001274737-26-000048, 0001274737-25-000071 |